We are live on
!
Find out more
Axa Portfolio holdings
AUM
$91.9M
1-Year Est. Return
27.41%
This Fund
S&P 500
This Quarter
Est. Return
+8.53%
1 Year Est. Return
+27.41%
3 Year Est. Return
+100.68%
5 Year Est. Return
+129.89%
10 Year Est. Return
+554.73%
AUM
$199M
AUM Growth
-$34.6B
(-99%)
Cap. Flow
-$35.1B
Cap. Flow
% of AUM
-17,587.21%
Top 10 Holdings %
Top 10 Hldgs %
62.92%
Holding
1,077
New
–
Increased
3
Reduced
57
Closed
1,016
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Core MSCI Emerging Markets ETF
IEMG
|
+$6.03M |
| 2 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$3.53M |
| 3 |
Vanguard S&P 500 ETF
VOO
|
+$1.02M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$2.49B |
| 2 |
Microsoft
MSFT
|
+$2.09B |
| 3 |
Apple
AAPL
|
+$1.44B |
| 4 |
Amazon
AMZN
|
+$1.36B |
| 5 |
Meta Platforms (Facebook)
META
|
+$721M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 29.46% |
| 2 | Technology | 21.6% |
| 3 | Consumer Discretionary | 12.36% |
| 4 | Financials | 10.02% |
| 5 | Communication Services | 9% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
551
Idexx Laboratories
IDXX
$40.5B
| – | – |
-59,141
| Closed | -$31.7M |
|
552
IES Holdings
IESC
$12.8B
| – | – |
-19,998
| Closed | -$2.96M |
|
553
IDEX
IEX
$16.4B
| – | – |
-37,275
| Closed | -$6.54M |
|
554
International Flavors & Fragrances
IFF
$21.6B
| – | – |
-11,725
| Closed | -$862K |
|
555
Innovative Industrial Properties
IIPR
$1.57B
| – | – |
-58,368
| Closed | -$3.22M |
|
556
Illumina
ILMN
$34.7B
| – | – |
-6,842
| Closed | -$653K |
|
557
Immunocore
IMCR
$1.64B
| – | – |
-94,919
| Closed | -$2.98M |
|
558
Imperial Oil
IMO
$63.9B
| – | – |
-32,551
| Closed | -$2.59M |
|
559
Immunome
IMNM
$2.75B
| – | – |
-179,519
| Closed | -$1.67M |
|
560
Incyte
INCY
$24.8B
| – | – |
-85,450
| Closed | -$5.82M |
|
561
Infosys
INFY
$45.3B
| – | – |
-716,993
| Closed | -$13.3M |
|
562
Ingredion
INGR
$6.25B
| – | – |
-15,906
| Closed | -$2.16M |
|
563
Insmed
INSM
$26.5B
| – | – |
-226,603
| Closed | -$22.8M |
|
564
Inspire Medical Systems
INSP
$2.14B
| – | – |
-14,109
| Closed | -$1.83M |
|
565
Intel
INTC
$536B
| – | – |
-723,287
| Closed | -$16.2M |
|
566
Intuit
INTU
$86.3B
| – | – |
-179,258
| Closed | -$141M |
|
567
Innoviva
INVA
$1.51B
| – | – |
-35,622
| Closed | -$716K |
|
568
Invitation Homes
INVH
$16.4B
| – | – |
-11,411
| Closed | -$374K |
|
569
Ionis Pharmaceuticals
IONS
$7.8B
| – | – |
-566,883
| Closed | -$22.4M |
|
570
International Paper
IP
$18.2B
| – | – |
-17,384
| Closed | -$814K |
|
|
IPG
571
DELISTED
Interpublic Group of Companies
IPG
| – | – |
-15,873
| Closed | -$389K |
|
572
IQVIA
IQV
$44.7B
| – | – |
-86,904
| Closed | -$13.7M |
|
573
Iron Mountain
IRM
$34.1B
| – | – |
-101,843
| Closed | -$10.4M |
|
|
ISPO
574
DELISTED
Inspirato
ISPO
| – | – |
-364,571
| Closed | -$1.24M |
|
575
Intuitive Surgical
ISRG
$135B
| – | – |
-686,237
| Closed | -$373M |
|
Similar funds
VI
FA
PBCM
CCAM
GBA
AWP
HI
DCA
Axa's Q3 2025 Portfolio in Review
As of Q3 2025, Axa held 1,077 positions worth $199M, down 99% from $34.8B the previous quarter. Its ten largest holdings account for 63% of the portfolio.
Axa withdrew a net $35.1B in Q3 2025, closing 1,016 positions and reducing 57 holdings. Its most notable exit was Broadcom, an estimated $666M position sold in full.
By sector, the portfolio is most concentrated in Miscellaneous at 29% of assets, up from 0.59% a quarter earlier, followed by Technology and Consumer Discretionary.
Against the trend, Axa added an estimated $6.03M to iShares Core MSCI Emerging Markets ETF.
- Axa added most to iShares Core MSCI Emerging Markets ETF in Q3 2025, an estimated $6.03M increase.
- Axa's biggest Q3 2025 reduction was NVIDIA, cutting an estimated $2.49B.
- Axa fully exited Broadcom in Q3 2025, selling an estimated $666M.
- Axa's ten largest holdings make up 63% of its $199M portfolio in Q3 2025.
- Axa opened 0 new positions and closed 1,016 in Q3 2025.
- Axa's portfolio value fell 99% quarter-over-quarter to $199M.
Based on Axa's 13F filing for Q3 2025, filed 14 Nov 2025.